{
  "drug_id": "D413D3EC269",
  "canonical_name": "medi6570",
  "total_pmids": 2,
  "evidence_count": {
    "benefit": 2,
    "harm": 0,
    "neutral": 0,
    "unknown": 0
  },
  "evidence_blocks": [
    {
      "pmid": "36688371",
      "title": "Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Background Blockade of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a potentially attractive mechanism for lowering inflammatory and lipid risk in patients with atheroscleros",
      "confidence": "medium"
    },
    {
      "pmid": "40999229",
      "title": "Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "The lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) is a key scavenger receptor for oxidized low-density lipoprotein cholesterol (oxLDL), which promotes inflammation and atherosc",
      "confidence": "medium"
    }
  ],
  "top_pmids": [
    "36688371",
    "40999229"
  ]
}